Vaccines for preventing anthrax

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Donegan, Sarah ^a   Bellamy, Richard ^b   Gamble, Carrol L ^c  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIBODY; IMMUNOGLOBULIN G; INACTIVATED VACCINE; LIVE VACCINE; PROTECTIVE ANTIGEN ANTIBODY; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANOREXIA; ANTHRAX; ANTIBODY TITER; ARM SWELLING; BACILLUS ANTHRACIS; BACTERIAL IMMUNITY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL; CLUSTER ANALYSIS; COCHRANE LIBRARY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EMBASE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE CONTUSION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LYMPHADENOPATHY; MALAISE; MEDLINE; MORTALITY; MYALGIA; NAUSEA; PRURITUS; RESPIRATORY TRACT DISEASE; REVIEW; SENSITIVITY ANALYSIS; SEROCONVERSION; SEX DIFFERENCE; SKIN DISCOLORATION; SMEAR; SUBCUTANEOUS NODULE; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; USSR;

EID: 70349084215     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006403.pub2     Document Type: Review

References (33)

1. Burgasov P, Cherkasskij B, Knop A, Utegenov K. Epidemiological efficacy of the anthrax STI vaccine. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii 1976;9:27-35.
2. Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Human Vaccines 2007;3(5):205-211 (Pubitemid 47598179)
3. Gorse G, Keitel W, Keyserling H, Taylor D, Lock M, Alves K, et al.Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial. Vaccine 2006;24(33-34):5950-5959 (Pubitemid 44080366)
4. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, et al.Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008;300(13):1532-1543
5. Pittman P, Kim-Ahn G, Pifat D, Coonan K, Gibbs P, Little S, et al.Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002;20(9-10):1412-1420 (Pubitemid 34131683)
6. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. American Journal of Public Health 1962;52(4):632-645
7. Derbin M, Sadovoj N, Tarumov V, Garin N. A comparative study of humoral anti-anthrax immunity in animals and humans immunized with live and chemical vaccines, UDK. Moscow: Central Scientific Research Institute of Epidemiology, 1981:1-7.
8. Grunow R, Porsch-Özcürümez M, Splettstoesser W, Buckendahl A, Hahn U, Beyer W. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. Vaccine 2007;25(18):3679-3683 (Pubitemid 46584757)
9. Hepburn M, Hugh Dyson E, Simpson A, Brenneman K, Bailey N, Wilkinson L, et al.Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine. Vaccine 2007;25(32):6089-6097 (Pubitemid 47082462)
10. Shlyakhov E, Rubinstein E. Delayed hypersensitivity after anthrax vaccination. II. Delayed hypersensitivity in humans vaccinated against anthrax [Hypersensibilite retardee charbonneuse post-vaccinale. II -Hypersensibilite retardee chez l'homme vaccine contre le charbon]. Medecine Tropicale 1994;54(2):133-136
11. Shevtsov AN, Darmov IV, Saîtseva GA, Borovskoî DV, Menovshchikov VA, Kunof VK, et al.Assessment of immunity and allergy after vaccination with dry combined anthrax vaccine. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2007;5:51-53
12. NCT00057525. A Phase 1 study of safety and immunogenicity of e. coli-derived recombinant protective antigen (rPA), a new anthrax vaccine administered by the intramuscular (IM) route in healthy adults. clinicaltrials.gov/ct2/show/NCT00057525 (accessed 12 January 2007).
13. NCT00063843. A Phase I, dose-escalating study to assess the safety, tolerability, and immunogenicity of recombinant anthrax protective antigen vaccine (rPA) administered in two intramuscular doses to healthy adults. clinicaltrials.gov/ct2/show/NCT00063843 (accessed 12 January 2007).
14. NCT00100724. A Phase 2 multi-center, randomized dose-finding trial of rPA-102 vaccine in healthy adult volunteers. clinicaltrials.gov/ct2/show/ NCT00100724 (accessed 12 January 2007).
15. NCT00103467. A Phase 1 trial to evaluate the safety and immunogenicity of an anthrax recombinant protective antigen vaccine. clinicaltrials.gov/ct2/show/ NCT00103467 (accessed 12 January 2007).
16. NCT00114621. Anthrax vaccine clinical trials. clinicaltrials.gov/ct2/ show/NCT00114621 (accessed 12 January 2007).
17. Marano N, Babcock J, Keitel W, Keyserling H, Parker S, Poland P, et al.Interim analysis of anthrax vaccine human reactogenicity and immunogenicity clinical trial. Personal correspondence (email).
18. * NCT00119067. Anthrax vaccine adsorbed: human reactogenicity and immunogenicity trial to address change in route of administration and dose reduction. clinicaltrials.gov/ct2/show/NCT00119067 (accessed 12 January 2007).
19. NCT00133484. A Phase II study to assess the safety, tolerability, immunogenicity, and optimal primary schedule of 3 recombinant protective antigen (rPA) anthrax vaccines administered in two intramuscular doses to healthy adults. clinicaltrials.gov/ct2/show/NCT00133484 (accessed 12 January 2007).
20. NCT00170456. A double-blind, parallel-group study of the safety, tolerability and immunogenicity of a range of doses and dosing schedules of Recombinant (rPA Based) Anthrax Vaccine in healthy subjects. clinicaltrials.gov/ct2/show/NCT00170456 (accessed 12 January 2007).
21. NCT00170469. A Phase II, dose ranging multi-centre, single blind, parallel-group, controlled study of the safety, tolerability and immunogenicity of recombinant (rPA based) anthrax vaccine compared with anthrax vaccine adsorbed in a healthy population. clinicaltrials.gov/ct2/show/NCT00170469 (accessed 12 January 2007).
22. Centers for Disease Control and Prevention (CDC). What is the anthrax vaccine?. www.cdc.gov/ncidod/dbmd/diseaseinfo/anthrax-g.htm#whatisvacc (accessed 9 March 2006).
23. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. New England Journal of Medicine 1999;341(11):815-826
24. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al.Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287(17):2236-2252
25. Jollenbeck LM, Zwanziger LL, Durch JS, Strom BL, editors. The anthrax vaccine. Is it safe? Does it work?. Washington, DC: National Academy Press, 2002.
26. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-46 (Pubitemid 32682008)
27. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
28. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, et al.In vitro correlate of immunity in a rabbitmodel of inhalational anthrax. Vaccine 2001;19(32):4768-4773 (Pubitemid 32800762)
29. Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, et al.Search for correlates of protective immunity conferred by anthrax vaccine. Infection and Immunity 2001;69(5):2888-2893 (Pubitemid 32332179)
30. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
31. Salisbury DM, Begg NT. Anthrax. Immunisation against infectious disease. London: HMSO, 1996:61-63
32. Jefferson T, Demicheli V, Deeks J, Graves P, Pratt M, Rivetti D. Vaccines for preventing anthrax. Cochrane Database of Systematic Reviews 1998, Issue 1. [DOI: 10.1002/14651858.CD000975.pub2]
33. Jefferson T, Demicheli V, Deeks J, Graves P, PrattM, Rivetti D. Vaccines for preventing anthrax. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: DOI: 10.1002/14651858.CD000975]